| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Not applicable. Dipotassium tetrachloroplatinate is an inorganic platinum salt and a synthetic precursor, not a drug with a specific biological target. Its primary use is as a chemical reagent for the synthesis of platinum-based anticancer drugs. The final drugs (e.g., cisplatin) target DNA, forming intra- and interstrand crosslinks that interfere with DNA replication and transcription, leading to apoptosis in cancer cells. However, K2PtCl4 itself has no direct therapeutic activity.
|
|---|---|
| ln Vitro |
Dipotassium tetrachloroplatinate is an inorganic platinum salt used as a precursor for synthesizing cisplatin and other platinum-based anticancer agents. Cisplatin, derived from K2PtCl4, is a highly effective chemotherapy drug used to treat various solid tumors including testicular, ovarian, and lung cancers. The biological activity of K2PtCl4 itself is not the focus; its utility is in the synthesis of bioactive platinum(II) complexes. It is also used in catalysis.
|
| ln Vivo |
No specific in vivo data is available for dipotassium tetrachloroplatinate as a drug, as it is not administered as a therapeutic agent. The in vivo activity of cisplatin, derived from K2PtCl4, is well-established: cisplatin induces tumor regression in animal xenograft models and is approved for human use. However, the precursor itself is not used for in vivo administration due to its chemical reactivity and lack of pharmacological activity.
|
| Enzyme Assay |
Not applicable. Dipotassium tetrachloroplatinate is a synthetic precursor, not a test compound in non-cellular enzyme binding assays. A standard protocol for cisplatin synthesis from K2PtCl4: K2PtCl4 (1 equiv, 4.15 g, 10 mmol) is dissolved in water (50 mL) at 60degC. KI (3.32 g, 20 mmol, 2 equiv) is added with stirring to form K2PtI4. NH3 solution (2.5 mL of 30% NH3 in 5 mL water, 2.5 equiv) is added dropwise. After 30 minutes, the yellow precipitate (cisplatin) is collected, washed, and recrystallized from DMF. Purity is assessed by elemental analysis and HPLC. The product cisplatin is then tested for anticancer activity.
|
| Cell Assay |
Not applicable. Dipotassium tetrachloroplatinate is used as a starting material for the synthesis of platinum-based drugs, not as a test compound in cell-based assays. The final platinum complexes derived from K2PtCl4 (e.g., cisplatin) are tested in cell-based assays. A typical cytotoxicity assay for cisplatin: Cancer cells (e.g., HeLa, A549, MCF-7) are seeded in 96-well plates and treated with cisplatin (0.1-100 uM) for 48-72 hours. Cell viability is measured by MTT or CellTiter-Glo. The IC50 for cisplatin in most sensitive cell lines is 1-20 uM. K2PtCl4 itself is not used in such assays due to its instability and non-specific reactivity.
|
| Animal Protocol |
Not applicable. Dipotassium tetrachloroplatinate is not administered to animals as a drug. The platinum drugs derived from it, such as cisplatin, are administered in animal studies. A typical cisplatin in vivo protocol: Female BALB/c nude mice (6-8 weeks old) bearing subcutaneous xenografts of cancer cells (e.g., 5×10⁶ A549 cells) are administered cisplatin intraperitoneally at doses of 3-6 mg/kg once weekly for 3-4 weeks. Tumor volume is measured twice weekly. Nephrotoxicity, myelosuppression, and weight loss are monitored as toxicity endpoints. The precursor K2PtCl4 is not used in such studies.
|
| ADME/Pharmacokinetics |
Not applicable. Dipotassium tetrachloroplatinate is a synthetic precursor for platinum-based drugs, not a therapeutic agent. Its pharmacokinetics are not relevant to drug development. The platinum-based drugs derived from it (e.g., cisplatin) have well-characterized PK: cisplatin is administered intravenously, has a half-life of 20-30 minutes for the initial distribution phase and 2-4 hours for the terminal elimination phase, is distributed to all tissues but does not cross the blood-brain barrier efficiently, and is primarily excreted unchanged in urine.
|
| Toxicity/Toxicokinetics |
K2PtCl4 is a platinum coordination compound that can cause skin, eye, and respiratory tract irritation upon contact. As a platinum salt, it may have sensitizing properties and can cause allergic reactions in susceptible individuals. Platinum compounds are also known to be genotoxic. Appropriate personal protective equipment (gloves, lab coat, safety goggles) should be used when handling this compound. Work in a fume hood to avoid inhalation of dust. For research use only, not for human consumption.
|
| References | |
| Additional Infomation |
K2PtCl4 is not a drug; it is an inorganic chemical precursor for the synthesis of platinum-based anticancer drugs. It is also known as Potassium tetrachloroplatinate(II). Appearance: Red-brown crystalline solid. Molecular weight: 415.09 g/mol. It is soluble in water and DMSO. For research and chemical synthesis use only. Not for human therapeutic applications.
|
| Molecular Formula |
CL4K2PT
|
|---|---|
| Molecular Weight |
415.09
|
| Exact Mass |
414.765
|
| CAS # |
10025-99-7
|
| Related CAS # |
13965-91-8 (Parent)
|
| PubChem CID |
61440
|
| Appearance |
Red to reddish brown solid powder
|
| Density |
3.38 g/mL at 25 °C(lit.)
|
| Melting Point |
250°C
|
| LogP |
2.756
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
19.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Pt-2](Cl)(Cl)(Cl)Cl.[K+].[K+]
|
| InChi Key |
RVRDLMCWUILSAH-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/4ClH.2K.Pt/h4*1H;;;/q;;;;2*+1;+2/p-4
|
| Chemical Name |
dipotassium;tetrachloroplatinum(2-)
|
| Synonyms |
Potassium tetrachloroplatinate(Ⅱ)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4091 mL | 12.0456 mL | 24.0912 mL | |
| 5 mM | 0.4818 mL | 2.4091 mL | 4.8182 mL | |
| 10 mM | 0.2409 mL | 1.2046 mL | 2.4091 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
